Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions
Cancers · 09.01.2026 · 18 (2) · 216
DOI: 10.3390/cancers18020216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.01.2026. Verfasst von Melanie Winter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Fr…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Advances in molecular pathology have transformed NSCLC (Non-Small Cell Lung Cancer) diagnosis, prognosis, and treatment by enabling precise tumor characterization and targeted therapeutic strategies. We review key genomic alterations in NSCLC, including EGFR (epidermal growth factor receptor) mutations, ALK (anaplastic lymphoma kinase) and ROS1 (ROS proto-oncogene 1) rearrangements, BRAF (B-Raf proto-oncogene serine/threonine kinase) mutations, MET (mesenchymal–epithelial transition factor) alterations, KRAS (Kirsten rat sarcoma) mutations, HER2 (human epidermal growth factor receptor 2) alterations and emerging NTRK (neurotrophic receptor tyrosine kinase) fusions and AXL-related pathways.
Methods
A total of 48 patients with NSCLC was analyzed, including 22 women and 26 men (mean age 70 years, range 44–86). Tumor specimens were classified histologically as adenocarcinomas (n = 81%) or squamous cell carcinomas (n = 19%). Smoking history, PD-L1 (programmed death-ligand 1) expression, and genetic alterations were assessed. NGS (Next-generation sequencing) identified genomic variants, which were classified according to ACMG (American College of Medical Genetics and Genomics) guidelines.
Results
The cohort consisted of 29 former smokers, 13 current smokers, and 5 non-smokers (12%), with a mean smoking burden of 33 pack years. PD-L1 TPS (tumor proportion score) was ≥50% in 10 patients, ≥1–
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
- University Hospital Frankfurt MVZ GmbH, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
- Molecular Health, Kurfuersten-Anlange 21, 69115 Heidelberg, Germany.
ORCID-Profile: Marc-Alexander Rauschendorf
Zitieren
APA
Winter, M., Jeroch, J., Wetz, M., Rauschendorf, M. A., & Wild, P. J. (2026). Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. Cancers, 18(2), 216. https://doi.org/10.3390/cancers18020216
Vancouver
Winter M, Jeroch J, Wetz M, Rauschendorf MA, Wild PJ. Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. Cancers. 2026;18(2):216. doi:10.3390/cancers18020216
BibTeX
@article{Winter2026,
author = {Winter, Melanie and Jeroch, Jan and Wetz, Maximilian and Rauschendorf, Marc-Alexander and Wild, Peter J},
title = {Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions},
journal = {Cancers},
year = {2026},
volume = {18},
number = {2},
pages = {216},
doi = {10.3390/cancers18020216}
}
EUVIMED